ArticleInternational journal of nanomedicine2022
Targeted Delivery of Nanovaccine to Dendritic Cells via DC-Binding Peptides Induces Potent Antiviral Immunity in vivo.
Article in International journal of nanomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Immunoinformatics Design of a Broad-Spectrum Multi-Epitope Vaccine Targeting HA2 and M1 of H9N2 AIV.Microorganisms · 2026Article
- Engineered PCV2 VLPs for Antigen Delivery: A Platform for Next-Generation Veterinary Vaccines.Transboundary and emerging diseases · 2026Review
- NFATc1 regulates LAG3+CD8+ T cells in the spleen of mice infected with Plasmodium yoelii NSM.PLoS neglected tropical diseases · 2025Article
- Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy.iScience · 2025Article
- The Role of Dendritic Cells in Adaptive Immune Response Induced by OVA/PDDA Nanoparticles.Vaccines · 2025Article
- Enhancing Vaccine Efficacy and Stability: A Review of the Utilization of Nanoparticles in mRNA Vaccines.Biomolecules · 2024Review
- Immune Responses Induced by a RecombinantViruses · 2024Article
- Review
- Engineering customized nanovaccines for enhanced cancer immunotherapy.Bioactive materials · 2024Review
- Targeting lymph nodes for enhanced cancer vaccination: From nanotechnology to tissue engineering.Materials today. Bio · 2024Review
- Microbiome and Prostate Cancer: Emerging Diagnostic and Therapeutic Opportunities.Pharmaceuticals (Basel, Switzerland) · 2024Review
- A novel "prime and pull" strategy mediated by the combination of two dendritic cell-targeting designs induced protective lung tissue-resident memory T cells against H1N1 influenza virus challenge.Journal of nanobiotechnology · 2023Article
- Review
- Multiepitope Subunit Peptide-Based Nanovaccine against Porcine Circovirus Type 2 (PCV2) Elicited High Antibody Titers in Vaccinated Mice.Molecules (Basel, Switzerland) · 2023Article
- Recent advances in antigen targeting to antigen-presenting cells in veterinary medicine.Frontiers in immunology · 2023Review
- Virus-like Particles for TEM Regulation and Antitumor Therapy.Journal of functional biomaterials · 2022Review
- A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles.Journal of nanobiotechnology · 2022Article
- Synthesis & Evaluation of Novel Mannosylated Neoglycolipids for Liposomal Delivery System Applications.Pharmaceutics · 2022Article
- The truncated form of flagellin (tFlic) provides the 2dCap subunit vaccine with better immunogenicity and protective effects in mice.Animal diseases · 2022Article
Corrections and comments
- Expression of concern
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dendritic cell (DC) targeted antigen delivery is a promising strategy to enhance vaccine efficacy and delivery of therapeutics. Self-assembling peptide-based nanoparticles and virus-like particles (VLPs) have attracted extensive interest as non-replicating vectors for nanovaccine design, based on their unique properties, including molecular specificity, biodegradability and biocompatibility. DCs are specialized antigen-presenting cells involved in antigen capture, processing, and presentation to initiate adaptive immune responses. Using DC-specific ligands for targeted delivery of antigens to DCs may be utilized as a promising strategy to drive efficient and strong immune responses. Methods: In this study, several candidates for DC-binding peptides (DCbps) were individually integrated into C-terminal of porcine circovirus type 2 (PCV2) Cap, a viral protein that could self-assemble into icosahedral VLPs with 60 subunits. The immunostimulatory adjuvant activity of DC-targeted VLPs was further evaluated in a vaccine model of PCV2 Cap. Results: With transmission electron microscopy (TEM), Conclusion: This study described the potential of DC-binding peptides for further improved antigen delivery and vaccine efficacy, explainning nanovaccine optimization in relation to a range of emerging and circulating infectious pathogens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.